The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide
Open accessAbstract
Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly attractive as it has superior stability and dry powder inhaler is relatively easy to use. A safe and effective mRNA delivery vector as well as a suitable particle engineering method are required to produce a dry powder formulation that is respirable and mediates robust transfection in the lung. Here, we introduce a novel RNA delivery vector, PEG12KL4, in which the synthetic cationic KL4 peptide is attached to a monodisperse linear PEG of 12-mers. The PEG12KL4 formed nano-sized complexes with mRNA at 10:1 ratio (w/w) and mediated effective transfection on human lung epithelial cells. PEG12KL4/mRNA complexes were successfully formulated into dry powder by spray drying (SD) and spray freeze drying (SFD) techniques. Both SD and SFD powder exhibited satisfactory aerosol properties for inhalation. More importantly, the biological activity of the PEG12KL4 /mRNA complexes were successfully preserved after drying. Using luciferase mRNA, the intratracheal administration of the liquid or powder aerosol of PEG12KL4 /mRNA complexes at a dose of 5 μg mRNA resulted in luciferase expression in the deep lung region of mice 24 h post-transfection. The transfection efficiency was superior to naked mRNA or lipoplexes (Lipofectamine 2000), in which luciferase expression was weaker and restricted to the tracheal region only. There was no sign of inflammatory response or toxicity of the PEG12KL4 /mRNA complexes after single intratracheal administration. Overall, PEG12KL4 is an excellent mRNA transfection agent for pulmonary delivery. This is also the first study that successfully demonstrates the preparation of inhalable dry powder mRNA formulations with in vivo transfection efficiency, showing the great promise of PEG12KL4 peptide as a mRNA delivery vector candidate for clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“[2,3], but these early promising results did not immediately translate into clinic benefits due to the concerns with mRNA instability, risk of innate immunogenicity and inefficient in vivo delivery.”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
Lai, S. K., Wang, Y.-Y., & Hanes, J. S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.002 · Cited by 1,863
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
PEGylation for enhancing nanoparticle diffusion in mucus
Huckaby, J. T., & Lai, S. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.08.010 · Cited by 484
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium
Patel, A. K., Kaczmarek, J. C., Bose, S., Kauffman, K. J., Mir, F. F., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2019) · Advanced Materials · doi:10.1002/adma.201805116 · Cited by 383
Flagged first, then by citations
Research works printed but not linked: 1
- Liu, 2015, Freeze-drying of proteins, Methods in molecular biology (Clifton, N.J.), 1257, 459
Cited by
Sorted by citations
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Formulation and Delivery Technologies for mRNA Vaccines
Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228
Delivery Strategies for mRNA Vaccines
Ramachandran, S., Satapathy, S. R., & Dutta, T. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00417-5 · Cited by 191
Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments
Zhang, H., Leal, J., Soto, M. R., Smyth, H. D. C., & Ghosh, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111042 · Cited by 163
Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung
Rotolo, L., Vanover, D. A., Bruno, N. C., Peck, H. E., Zurla, C., Murray, J., Noel, R. K., O’Farrell, L., Araínga, M., Orr‐Burks, N., et al. (2022) · Nature Materials · doi:10.1038/s41563-022-01404-0 · Cited by 157
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160
Ai, L., Li, Y., Zhou, L., Yao, W., Zhang, H., Hu, Z., Han, J., Wang, W., Wu, J., Xu, P., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00517-9 · Cited by 148
Pramanik, S., Mohanto, S., Manne, R., Rajendran, R. R., Deepak, A., Edapully, S. J., Patil, T., & Katari, O. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00491 · Cited by 144
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
The nano delivery systems and applications of mRNA
Li, M., Li, Y., Li, S., Jia, L., Wang, H., Li, M., Deng, J., Zhu, A., Ma, L., Li, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113910 · Cited by 127
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
mRNA vaccines for COVID-19 and diverse diseases
Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M. F., He, H., Chang, J. K., Liang, X., Weng, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.032 · Cited by 121
Inhaled RNA Therapy: From Promise to Reality
Chow, M. Y. T., Qiu, Y., & Lam, J. K. W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.002 · Cited by 105
Dry powder pharmaceutical biologics for inhalation therapy
Chang, R. Y. K., Chow, M. Y. T., Khanal, D., Chen, D., & Chan, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.017 · Cited by 109
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy
Jin, Z., Gao, Q., Wu, K., Ouyang, J., Guo, W., & Liang, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115111 · Cited by 110
Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
Huang, M., Zhang, M., Zhu, H., Du, X., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.002 · Cited by 96
Heida, R., Hinrichs, W. L. J., & Frijlink, H. W. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903878 · Cited by 96
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery
Boisguérin, P., Konate, K., Josse, E., Vivès, É., & Deshayes, S. (2021) · Biomedicines · doi:10.3390/biomedicines9050583 · Cited by 91
Wang, H., Lu, Q., Zhang, X., Guan, J., & Mao, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.061 · Cited by 90
Cell-Penetrating Peptides: Emerging Tools for mRNA Delivery
Yokoo, H., Oba, M., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010078 · Cited by 88
Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 88
Chan, H. W., Chow, S., Zhang, X., Zhao, Y., Tong, H. H. Y., & Chow, S. F. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02559-y · Cited by 85
Emerging delivery approaches for targeted pulmonary fibrosis treatment
Diwan, R., Bhatt, H., Beaven, E., & Nurunnabi, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115147 · Cited by 81
Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA
Friis, K. P., Gracin, S., Oag, S., Leijon, A., Sand, E., Lindberg, B., Lázaro‐Ibáñez, E., Lindqvist, J., Whitehead, K. A., & Bak, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.031 · Cited by 79
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
Byun, M. J., Lim, J., Kim, S.-N., Park, D.-H., Kim, T. P., Park, W., & Park, C. G. (2022) · BioChip Journal · doi:10.1007/s13206-022-00052-5 · Cited by 78
A Review of Non-Invasive Drug Delivery through Respiratory Routes
Zhang, Y., Xu, D. W., Bai, L., Zhou, Y.-M., Zhang, H., & Cui, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091974 · Cited by 77
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Wei, J., & Hui, A. (2022) · Life · doi:10.3390/life12081254 · Cited by 71
Engineering the right formulation for enhanced drug delivery
Ke, W.-R., Chang, R. Y. K., & Chan, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114561 · Cited by 67
Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA
Miao, H., Huang, K., Li, Y., Li, R., Zhou, X., Shi, J., Tong, Z., Sun, Z., & Yu, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123050 · Cited by 66
Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics
Klipp, A., Burger, M., & Leroux, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115047 · Cited by 66
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery
Sarode, A., Patel, P., Vargas‐Montoya, N., Allawzi, A. M., Zhilin-Roth, A., Karmakar, S., Boeglin, L., Deng, H., Karve, S., & DeRosa, F. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01402-y · Cited by 64
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 58
Spray Freeze Drying of Biologics: A Review and Applications for Inhalation Delivery
Farinha, S., Sá, J. V., Lino, P. R., Galésio, M., Pires, J., Rodrigues, M. Â., & Henriques, J. G. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03442-4 · Cited by 62
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
AboulFotouh, K., Cui, Z., & Williams, R. O. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-01974-3 · Cited by 56
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Cancer-related micropeptides encoded by ncRNAs: Promising drug targets and prognostic biomarkers
Setrerrahmane, S., Li, M., Zoghbi, A., Lv, X., Zhang, S., Zhao, W., Lu, J., Craik, D. J., & Xu, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215723 · Cited by 58
Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
Neary, M. T., Mulder, L. M., Kowalski, P. S., MacLoughlin, R. J., Crean, A. M., & Ryan, K. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.012 · Cited by 63
Inhalation delivery technology for genome-editing of respiratory diseases
Chow, M. Y. T., Chang, R. Y. K., & Chan, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.001 · Cited by 54
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
Emerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
Arte, K. S., Chen, M., Patil, C. D., Huang, Y., Qu, L. L., & Zhou, Q. T. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.12.013 · Cited by 51
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 51
Novel formulations and drug delivery systems to administer biological solids
Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 50
Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer
Levačić, A. K., Berger, S., Müller, J., Wegner, A., Lächelt, U., Dohmen, C., Rudolph, C., & Wagner, E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.016 · Cited by 47
Polyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 46
Nanoparticles for local delivery of siRNA in lung therapy
Kubczak, M., Michlewska, S., Bryszewska, M. J., Aigner, A. M., & Йонов, М. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114038 · Cited by 48
Engineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46
Natural peptides for immunological regulation in cancer therapy: Mechanism, facts and perspectives
Zhang, Y., Liu, C., Wu, C., & Song, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114257 · Cited by 43
Surfactant Protein B Promotes Cytosolic SiRNA Delivery by Adopting a Virus-like Mechanism of Action
Guagliardo, R., Herman, L., Penders, J., Zamborlin, A., Keersmaecker, H. D., de Vyver, T. V., Verstraeten, S. L., Merckx, P., Mingeot‐Leclercq, M., Echaide, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c04489 · Cited by 43
mRNA delivery enabled by metal–organic nanoparticles
Gu, Y., Chen, J., Wang, Z., Liu, C., Wang, T., Kim, C., Ďuríková, H., Fernandes, S., Johnson, D. N., Rose, R. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53969-w · Cited by 44
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
Pulmonary surfactant as a versatile biomaterial to fight COVID-19
Herman, L., Smedt, S. C. D., & Raemdonck, K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.023 · Cited by 42
Are inhaled mRNA vaccines safe and effective? A review of preclinical studies
Jansen, E. M., Frijlink, H. W., Hinrichs, W. L. J., & Ruigrok, M. J. R. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2131767 · Cited by 37
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects
Xu, Y., Thakur, A., Zhang, Y., & Foged, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020177 · Cited by 38
Munir, M., Kett, V. L., Dunne, N., & McCarthy, H. O. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03256-4 · Cited by 37
Emerging trends in pulmonary delivery of biopharmaceuticals
Kunde, S. S., Ghosh, R., & Wairkar, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.003 · Cited by 35
Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials
Karimi-Sani, I., Molavi, Z., Naderi, S., Mirmajidi, S. H., Zare, I., Naeimzadeh, Y., Mansouri, A., Tajbakhsh, A., Savardashtaki, A., & Sahebkar, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02882-x · Cited by 39
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 37
Advances and prospects of mRNA vaccines in cancer immunotherapy
Liu, Y., Yan, Q., Zeng, Z., Fan, C., & Xiong, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189068 · Cited by 33
Nuclease activity: an exploitable biomarker in bacterial infections
González, J. G., & Hernández, F. J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049249 · Cited by 35
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34
Inhalable mRNA vaccines for respiratory diseases: a roadmap
Roh, E. H., Fromen, C. A., & Sullivan, M. O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.10.017 · Cited by 32
AboulFotouh, K., Xu, H., Moon, C., Williams, R. O., & Cui, Z. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121825 · Cited by 32
Pan, H. W., Seow, H. C., Lo, J. C. K., Guo, J., Zhu, L., Leung, S. W. S., Zhang, C., & Lam, J. K. W. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03331-w · Cited by 35
Novel Vectors and Administrations for mRNA Delivery
Bai, C., Wang, C., & Lu, Y. (2023) · Small · doi:10.1002/smll.202303713 · Cited by 32
Xu, Y., Zheng, Y., Ding, X., Wang, C., Hua, B., Hong, S., Huang, X., Lin, J., Zhang, P., & Chen, W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2219870 · Cited by 31
Spray drying: Inhalable powders for pulmonary gene therapy
Munir, M., Jena, L., Kett, V. L., Dunne, N., & McCarthy, H. O. (2021) · Biomaterials Advances · doi:10.1016/j.msec.2021.112601 · Cited by 32
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Inhalable Dry Powders for Lung mRNA Delivery
Gordon, A. G. R., Li, B., Witten, J. J., Nguyen, H. Q., & Anderson, D. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400509 · Cited by 36
Long-acting inhaled medicines: Present and future
Zhang, C., D’Angelo, D., Buttini, F., & Yang, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115146 · Cited by 28
Wang, Q., Bu, C., Dai, Q., Chen, J., Zhang, R., Zheng, X., Ren, H., Xin, X., & Li, X. (2024) · Advanced Science · doi:10.1002/advs.202309748 · Cited by 29
Strategies to deliver RNA by nanoparticles for therapeutic potential
Cox, A., Lim, S. A., & Chung, E. J. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100991 · Cited by 28
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Imaging drug delivery to the lungs: Methods and applications in oncology
Man, F., Tang, J., Swedrowska, M., Forbes, B., & de Rosales, R. T. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114641 · Cited by 27
Zhang, X., Cui, Y., Liang, R., Wang, G., Xiao, Y., Zhao, Z., Huang, Z., Huang, Y., Geng, J., Pan, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.013 · Cited by 25
Lü, Y., Tang, L., Zhang, M., & Liu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.896958 · Cited by 28
Encinas-Basurto, D., Eedara, B. B., & Mansour, H. M. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00671-0 · Cited by 24
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 25
Shao, Z., Chow, M. Y. T., Chow, S. F., & Lam, J. K. W. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03488-y · Cited by 22
Intratracheal Administration of Dry Powder Formulation in Mice
Qiu, Y., Liao, Q., Chow, M. Y. T., & Lam, J. K. W. (2020) · Journal of Visualized Experiments · doi:10.3791/61469 · Cited by 21
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 21
Soybean Oil‐Derived Lipids for Efficient mRNA Delivery
Tang, Z., Yu, F., Hsu, J. C., Shi, J., & Cai, W. (2023) · Advanced Materials · doi:10.1002/adma.202302901 · Cited by 20
Cui, Y., Huang, Y., Zhang, X., Lu, X.-Y., Xue, J., Wang, G., Hu, P., Xiao, Y., Zhao, Z., Pan, X., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.011 · Cited by 19
Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation
Seow, H. C., Cai, J., Pan, H. W., Luo, C., Wen, K., Situ, J., Wang, K., Cao, H., Leung, S. W. S., Yuan, S., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.029 · Cited by 19
Non-viral mRNA delivery to the lungs
Healy, L., Seto, B. Y., Cui, H., & Li, B. (2025) · Biomaterials Science · doi:10.1039/d5bm00322a · Cited by 22
Nucleic acid delivery by lipid nanoparticles for organ targeting
Guo, J., Gu, M., Chen, Y., Xiong, T., Zhang, Y., Chen, S., Li, M., Chen, X., & Peng, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.110849 · Cited by 18
Inhaled non-viral delivery systems for RNA therapeutics
Huang, C., Li, H., Duan, X., Zhang, P., Qi, S., Du, J., Song, X., Tong, A., & Yu, G. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.033 · Cited by 21
Ghanem, R., Laurent, V., Roquefort, P., Haute, T., Ramel, S., Gall, T. L., Aubry, T., & Montier, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010047 · Cited by 19
Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance
Qiu, Y., Clarke, M., Wan, L. T. L., Lo, J. C. K., Mason, A. J., & Lam, J. K. W. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01242 · Cited by 17
Wang, Z., Hao, D., Wang, Y., Zhao, J., Zhang, J., Rong, X., Zhang, J., Min, J., Qi, W. D., Su, R., et al. (2022) · Small · doi:10.1002/smll.202204959 · Cited by 18
Man, R. C. H., Qiu, Y., Leung, S. W. S., Fruhwirth, G. O., & Lam, J. K. W. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114177 · Cited by 17
Quaternization drives spleen-to-lung tropism conversion for mRNA-loaded lipid-like nanoassemblies
Huang, Y., Wu, J., Li, S., Liu, Z., Li, Z., Zhou, B., & Li, B. (2024) · Theranostics · doi:10.7150/thno.90071 · Cited by 16
Understanding Mucosal Physiology and Rationale of Formulation Design for Improved Mucosal Immunity
Biswas, M., Nurunnabi, M., & Khatun, Z. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00395 · Cited by 16
Soto, M. R., Lewis, M. M., Leal, J., Pan, Y., Mohanty, R. P., Veyssi, A., Maier, E. Y., Heiser, B. J., & Ghosh, D. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102375 · Cited by 20
Metadata
- Authors
- Qiu, Y., Man, R. C. H., Liao, Q., Kung, K. L. K., Chow, M. Y. T., & Lam, J. K. W.
- Affiliations
- University of Hong Kong (HK)
- The University of Sydney (AU)
- Corresponding author
- Lam, Jenny K.W.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 314
- Pages
- 102-115
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2980850909
- Cited by
- 178
- References
- 41
- Citations by year
- 2026: 11 · 2025: 28 · 2024: 25 · 2023: 37 · 2022: 36 · 2021: 24 · 2020: 15 · 2019: 1
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Controlled Release (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- University of Hong Kong (201711159172)
- King's College London
- National Natural Science Foundation of China (NSFC 81573373)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- mRNA delivery, pulmonary drug delivery, dry powder formulation, PEGylation, cationic peptides, spray drying, spray freeze drying, aerosol properties, intratracheal administration, luciferase expression, lipoplexes, dry powder inhaler, mRNA vaccines
- MeSH terms
- A549 Cells, Administration, Inhalation, Aerosols, Animals, Epithelial Cells, Female, Freeze Drying, Humans, Lipids, Lung, Mice, Inbred BALB C, Polyethylene Glycols, RNA, Messenger, Transfection, Intercellular Signaling Peptides and Proteins, Mice, Dry Powder Inhalers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
